Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

Core Viewpoint - Teva Pharmaceuticals has received a credit rating upgrade from Moody's, reflecting the company's strong performance and strategic focus on growth and debt reduction [1][2][3]. Group 1: Credit Rating Upgrade - Moody's has raised Teva's corporate credit rating to Ba1 with a stable outlook, up from Ba2 with a positive outlook [1]. - The upgrade is attributed to Teva's significant global scale, growth in branded franchises, stabilization of the generics business, and focus on debt reduction [2]. Group 2: Company Strategy and Performance - The upgrade is seen as a validation of Teva's "Pivot to Growth" strategy, which aims to enhance the company's financial health and investor access [3]. - Teva has a global workforce of 37,000 employees operating in 57 markets, focusing on both innovative medicines and generics [3].